ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company's cancer immunotherapies targets cancer stem cells (CSCs). Its product candidates include ICT-107, which completed phase II testing, and also a portfolio of other potential therapeutic immunotherapies using a range of approaches to treat cancer. ICT-107, the Company's lead product candidate, is a dendritic cell (DC) vaccine for the treatment of newly diagnosed glioblastoma multiforme (GBM), a type of brain cancer. In addition to ICT-107, the Company develops other therapeutic DC vaccines, including ICT-140 for ovarian cancer and ICT-121 for recurrent GBM. ICT-140 targets seven tumor-associated antigens expressed on ovarian cancer cells. ICT-121 specifically targets CD133, a CSC marker that is overexpressed in a variety of solid tumors, including ovarian, pancreatic, and breast cancers. Its product candidates also include stem cell therapies for cancer, which is in pre-clinical-stage.